Insights Without Animals: Leveraging Human-on-a-Chip & PBPK Modeling

The pharmaceutical industry is transitioning away from animal tests, per the recent FDA Roadmap. Scientists’ need for drug development insights without animals has spurred greater interest in New Approach Methodologies (NAMs), such as in silico modeling and in vitro assays like organ-on-a-chip.

This webinar will explore how Human-on-a-Chip (HoC) systems—combined with physiologically-based pharmacokinetic (PBPK) modeling—enable a powerful, human-relevant approach to predicting safety and efficacy in drug development. Speakers will showcase how HoC data can be translated into in vivo outcomes using biosimulation, with case studies illustrating regulatory and program-level impact.

Who should attend:

• R&D and translational leaders in biotech and pharma
• Toxicologists and DMPK scientists
• Clinical pharmacologists and regulatory professionals
• Modeling & simulation experts